Blocking Piezo2, a protein receptor that senses mechanical forces in tissues, may be a new way to slow IPF progression, per a ...

Neurodegenerative disorders have increasing incidence with limited treatment options. Approaches to target neuroinflammation in various neurodegenerative disorders, such as Alzheimer’s disease (AD), ...

In accordance with the NMPA approval, Gyre intends to pursue an adaptive Phase 2/3 clinical trial design, combining dose exploration with efficacy confirmation, to efficiently evaluate pirfenidone's ...

NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Chicago Atlantic BDC, Inc. ("LIEN” or the "Company”) (NASDAQ: LIEN), formerly ...

Gyre Therapeutics (GYRE) announced that the National Medical Products Administration, NMPA, of the People’s Republic of China, PRC, has ...

Gyre Therapeutics, Inc.’s GYRE share price has dipped by 14.60%, which has investors questioning if this is right time to buy ...

Researchers have found a potential new way to slow the progression of lung fibrosis and other fibrotic diseases by inhibiting ...

Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...

SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on organ ...

Keep this leaflet with the medicine. You may need to read it again. Esbriet contains the active ingredient pirfenidone. Esbriet is used to treat Idiopathic Pulmonary Fibrosis (IPF). IPF is a ...